Euangelion — original explanatory figure
Created 9 October 2026, America/Los_Angeles.
Original paper SVG composition and responsive data.
Original Euangelion composition from cited facts; no third-party image, artwork or layout reproduced.
Source basis: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer
Original factual source/check timestamps are unchanged by this stylistic revision.
Both groups received trastuzumab and pertuzumab. Group medians do not predict an individual outcome; overall survival remains immature.
After qualifying induction, group median progression-free survival is 24.9 months with tucatinib and 16.3 months with placebo, both with trastuzumab and pertuzumab, on a shared zero-to-30-month scale. The 8.6-month difference is arithmetic between group medians; it does not establish extra life or predict an individual outcome. Overall-survival results remain immature.